Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.084
Sell
RSI(14)
39.573
Neutral
STOCH(KDJ)(9,3,3)
44.153
Buy
ATR(14)
2.502
Low Volatility
CCI(14)
-33.344
Neutral
Williams %R
65.040
Sell
TRIX(12,20)
-0.420
Sell
StochRSI(14)
100.000
Buy
Incyte Corp
INCY92.260USD
+0.030+0.03%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
11.81BMarket Cap
14.00P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Incyte Corp
Currency: USD Updated: 2026-03-25Key Insights
Incyte Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 107.67.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incyte Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Incyte Corp Highlights
StrengthsRisks
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.12% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.14B.
Undervalued
The company’s latest PE is 13.99, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 207.27M shares, decreasing 0.83% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.30K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
107.674
Target Price
+19.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-25The current financial score of Incyte Corp is 9.40, ranking 4 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.51B, representing a year-over-year increase of 27.84%, while its net profit experienced a year-over-year increase of 48.74%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.25
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.74
Incyte Corp's Company Valuation
Currency: USD Updated: 2026-03-25The current valuation score of Incyte Corp is 6.71, ranking 114 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 13.99, which is 5775.39% below the recent high of 822.13 and 1.93% above the recent low of 13.72.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 20/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-25The current earnings forecast score of Incyte Corp is 7.33, ranking 105 out of 157 in the Pharmaceuticals industry. The average price target is 101.00, with a high of 129.00 and a low of 70.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
107.219
Target Price
+18.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Incyte Corp
INCY
27
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-25The current price momentum score of Incyte Corp is 7.00, ranking 56 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 99.58 and the support level at 87.06, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
91.268
Buy
MA10
92.129
Buy
MA20
94.630
Sell
MA50
99.380
Sell
MA100
100.728
Sell
MA200
90.134
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-25The current institutional shareholding score of Incyte Corp is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 105.58%, representing a quarter-over-quarter increase of 1.56%. The largest institutional shareholder is The Vanguard, holding a total of 19.82M shares, representing 9.96% of shares outstanding, with 3.18% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Baker Bros. Advisors LP
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
LSV Asset Management
Arrowstreet Capital, Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2026-03-25The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Incyte Corp is 8.15, ranking 27 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.87
VaR
+2.70%
240-Day Maximum Drawdown
+18.20%
240-Day Volatility
+35.49%
Return
Best Daily Return
60 days
+5.48%
120 days
+8.65%
5 years
+12.04%
Worst Daily Return
60 days
-8.24%
120 days
-8.24%
5 years
-8.62%
Sharpe Ratio
60 days
-0.83
120 days
+0.55
5 years
+0.23
Risk Assessment
Maximum Drawdown
240 days
+18.20%
3 years
+33.83%
5 years
+41.06%
Return-to-Drawdown Ratio
240 days
+3.69
3 years
+0.43
5 years
+0.06
Skewness
240 days
+0.44
3 years
+0.42
5 years
+0.14
Volatility
Realised Volatility
240 days
+35.49%
5 years
+32.01%
Standardised True Range
240 days
+2.83%
5 years
+2.08%
Downside Risk-Adjusted Return
120 days
+82.94%
240 days
+82.94%
Maximum Daily Upside Volatility
60 days
+26.54%
Maximum Daily Downside Volatility
60 days
+27.93%
Liquidity
Average Turnover Rate
60 days
+0.92%
120 days
+1.01%
5 years
--
Turnover Deviation
20 days
-12.85%
60 days
-9.75%
120 days
-1.57%
Peer Comparison
Pharmaceuticals
Incyte Corp
INCY
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
